ITOS logo

iTeos Therapeutics (ITOS) Company Overview

Profile

Full Name:

iTeos Therapeutics, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

July 24, 2020

Indexes:

Not included

Description:

iTeos Therapeutics is a biotechnology company focused on developing innovative cancer treatments. They create new drugs that help the immune system fight cancer more effectively. Their research aims to improve patient outcomes and provide better options for those with difficult-to-treat cancers.

Key Details

Price

$7.57

Annual Revenue

$12.60 M(-95.29% YoY)

Annual EPS

-$3.15(-223.05% YoY)

Annual ROE

-18.19%

Beta

1.10

Events Calendar

Earnings

Next earnings date:

Mar 6, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 6, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 16, 25 HC Wainwright & Co.
Buy
Dec 19, 24 Wells Fargo
Overweight
Dec 13, 24 HC Wainwright & Co.
Buy
Nov 15, 24 HC Wainwright & Co.
Buy
Sep 16, 24 HC Wainwright & Co.
Buy
Aug 13, 24 Wells Fargo
Overweight
Aug 12, 24 JP Morgan
Overweight
May 13, 24 HC Wainwright & Co.
Buy
Mar 12, 24 JP Morgan
Overweight
Mar 7, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
ITOS
zacks.comJanuary 13, 2025

iTeos Therapeutics (ITOS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
iTeos Therapeutics: A Perhaps Unjustified Decline To End 2024
ITOS
seekingalpha.comDecember 17, 2024

iTeos Therapeutics, Inc.'s lead candidate, belrestotug, shows promising response rates in lung cancer but faces challenges with increased toxicity and skepticism due to past failures in similar approaches. The company's financial health is strong, with over half a billion dollars in liquid assets and long-term investments, providing a substantial cushion for ongoing projects. Despite shelving inupadenant, the focus remains on belrestotug, with ongoing trials exploring its potential in various cancer indications.

iTeos to Participate in Upcoming Investor Conferences
iTeos to Participate in Upcoming Investor Conferences
iTeos to Participate in Upcoming Investor Conferences
ITOS
globenewswire.comNovember 26, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 26, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming conferences in December:

iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
iTeos Therapeutics: ESMO Data Showing Signs Of A Real Win For TIGIT
ITOS
seekingalpha.comSeptember 15, 2024

iTeos Therapeutics' belrestotug shows promising response rates in lung cancer trials, especially when combined with dostarlimab, despite significant safety concerns. Financially, ITOS has over 3 years of cash runway, bolstered by collaboration revenue, supporting its potential to reach critical milestones. The risks include small trial size, potential non-translation of response rates to survival benefits, and high-grade toxicities that could hinder approval.

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients
ITOS
globenewswire.comSeptember 14, 2024

- Clinically meaningful objective response rate (ORR) of 63.3-76.7% observed with belrestotug + dostarlimab combinations, with confirmed ORR (cORR) at ~60% for every dose - >30% cORR difference between belrestotug + dostarlimab vs dostarlimab monotherapy - Belrestotug + dostarlimab safety profile broadly consistent with known safety profile of checkpoint inhibitor combinations - GALAXIES Lung-301, global Phase 3 registration study, enrolling in same indication and setting - iTeos to host a conference call on Monday, September 16, 2024 at 8:00am ET

iTeos to Participate in Upcoming Investor Conferences
iTeos to Participate in Upcoming Investor Conferences
iTeos to Participate in Upcoming Investor Conferences
ITOS
globenewswire.comAugust 28, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 28, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that company management will participate in two upcoming investor conferences in September:

iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
iTeos Therapeutics Announces Late-Breaking Oral Presentation of Phase 2 GALAXIES Lung-201 Interim Data at the European Society for Medical Oncology Congress 2024
ITOS
globenewswire.comAugust 20, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 20, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that interim data from GALAXIES Lung-201, the Phase 2 platform study sponsored by iTeos' development partner GSK, assessing the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced or metastatic PD-L1 high non-small cell lung cancer, will be presented as a late-breaking oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024, being held September 13-17, 2024 in Barcelona, Spain.

ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
ITeos Therapeutics, Inc. (ITOS) Reports Q2 Loss, Tops Revenue Estimates
ITOS
zacks.comAugust 8, 2024

ITeos Therapeutics, Inc. (ITOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $1.04. This compares to loss of $0.96 per share a year ago.

iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
iTeos Therapeutics Announces Appointment of David Feltquate as Chief Medical Officer
ITOS
globenewswire.comAugust 5, 2024

WATERTOWN, Mass. and GOSSELIES, Belgium, Aug. 05, 2024 (GLOBE NEWSWIRE) --  iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced the appointment of David Feltquate, M.D., Ph.D., as Chief Medical Officer. In this role, Dr. Feltquate will be responsible for overseeing the Company's clinical development and regulatory strategies.

iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
iTeos Therapeutics: Rippling Waves Of TIGIT Pessimism
ITOS
seekingalpha.comJuly 8, 2024

iTeos Therapeutics is developing an anti-TIGIT molecule for various cancers, partnering with GSK and advancing to late-stage clinical studies. Their main clinical focus is belrestotug, aiming to differentiate from other anti-TIGIT approaches, with positive interim data readouts. Financially, ITOS has a strong balance sheet with significant cash reserves, but faces risks from unproven TIGIT targets and market valuation fluctuations.

  • 1(current)
  • 2
  • 1(current)
  • 2

FAQ

  • What is the ticker symbol for iTeos Therapeutics?
  • Does iTeos Therapeutics pay dividends?
  • What sector is iTeos Therapeutics in?
  • What industry is iTeos Therapeutics in?
  • What country is iTeos Therapeutics based in?
  • When did iTeos Therapeutics go public?
  • Is iTeos Therapeutics in the S&P 500?
  • Is iTeos Therapeutics in the NASDAQ 100?
  • Is iTeos Therapeutics in the Dow Jones?
  • When was iTeos Therapeutics's last earnings report?
  • When does iTeos Therapeutics report earnings?
  • Should I buy iTeos Therapeutics stock now?

What is the ticker symbol for iTeos Therapeutics?

The ticker symbol for iTeos Therapeutics is NASDAQ:ITOS

Does iTeos Therapeutics pay dividends?

No, iTeos Therapeutics does not pay dividends

What sector is iTeos Therapeutics in?

iTeos Therapeutics is in the Healthcare sector

What industry is iTeos Therapeutics in?

iTeos Therapeutics is in the Biotechnology industry

What country is iTeos Therapeutics based in?

iTeos Therapeutics is headquartered in United States

When did iTeos Therapeutics go public?

iTeos Therapeutics's initial public offering (IPO) was on July 24, 2020

Is iTeos Therapeutics in the S&P 500?

No, iTeos Therapeutics is not included in the S&P 500 index

Is iTeos Therapeutics in the NASDAQ 100?

No, iTeos Therapeutics is not included in the NASDAQ 100 index

Is iTeos Therapeutics in the Dow Jones?

No, iTeos Therapeutics is not included in the Dow Jones index

When was iTeos Therapeutics's last earnings report?

iTeos Therapeutics's most recent earnings report was on Nov 12, 2024

When does iTeos Therapeutics report earnings?

The next expected earnings date for iTeos Therapeutics is Mar 6, 2025

Should I buy iTeos Therapeutics stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions